1st. Quarter 2008 Presentation

Erik Christensen MD PhD
Chief Executive Officer

Ruben Ekbråten
Financial Controller

DiAGENiC

FOR EARLIER DISEASE DETECTION

1st Quarter Highlights

- New Patents Accepted on Alzheimer's Disease for Europe
- Patient inclusion completed in the Indian multi centre study
- MoU for distribution of breast cancer test in India
- Development of a diagnostic product for Parkinson's disease has been initiated
- Increased global recognition following scientific presentations

Agenda:

1st Quarter 2008 Presentation

- 1st Quarter Highlights
- 1st Quarter Finance
- Product Development and Clinical Studies
- Commercial Strategies
- Outlook

Agenda:

1st Quarter 2008 Presentation

- 1st Quarter Highlights
- **1st Quarter Finance**
- Product Development and Clinical Studies
- Commercial Strategies
- Outlook

Finance, Profit & Loss





Finance, Cash Position



- Cash and cash equivalents NOK 12.4m at 31 March 2008
- Board of directors have the power of attorney to raise share capital by up to 8m shares
- Kaupthing engaged as manager in the equity offering

Finance, 2008 outlook

- Key milestones for Q2 ’08
  - Equity offering expected to be completed
- High activity with limited increases in burn rate for Q2 ’08 compared with previous quarter

Agenda:

1st Quarter 2008 Presentation

- 1st Quarter Highlights
- 1st Quarter Finance
- **Product Development and Clinical Studies**
- Commercial Strategies
- Outlook

Central Theme in DiaGenic Technology



DNA

RNA



Protein



- RNA plays a central role in translating what is written in our genes to what is expressed in our bloodstream
- RNA expression is measured by qRT-PCR and forms the basis of our proprietary gene signature

DiaGenic's Product Development Focus

Alzheimers Disease

Parkinsons Disease

Breast Cancer

DiaGenic's Product Development Focus

Alzheimer's Disease

DiaGenic Studies

Summary Table of AD Clinical Studies

Study size includes both patient and control samples

Study Code	Description	Study size (patients)*	Current Status
AD0501	AB1700 Discovery Study	280	Completed
AD060M	TaqMan® Pilot Study	59	Completed
prAD106	CodeLink Gene Validation	120	Completed
AD0602	TaqMan® Gene Validation	120	Completed
AD0702	TaqMan® Prototype Optimization	104	Completed
AD0601	FUGE AD Norway	900	Ongoing
AD0701	FUGE AD Sweden	190	Ongoing
AD0703	New Platform Gene Validation	104	Ongoing
AD0706	EDAR EU study for AD biomarkers	360	Ongoing
AD0704	UCD multiethnicity Study (FDA)	TBD	Planning phase

*Study size indicates the total number of patients recruited to each study

CLINICAL GRADING OF ALZHEIMER'S DISEASE AND EARLY DETECTION WITH A BLOOD BASED GENE EXPRESSION SIGNATURE

5th International Pharmaco-Economic Conference on Alzheimer's Disease (IPECAD), Newark, USA



CLINICAL GRADING OF ALZHEIMER'S DISEASE AND EARLY DETECTION WITH A BLOOD BASED GENE EXPRESSION SIGNATURE

DIAGENIC

Anders Lönneborg[1], Peter Wetterberg[2] Solve Sæbø[3], Torbjørn Lindahl[1], Magdalena Kauczynska[1], Phil D. Rye[1], Marianne Jensen[1], Ken Bårdsen[1], Lena Kristiansen[1], Birgitte Booij[1], Praveen Sharma[1]

[1]DiaGenic ASA, Grenseveien 92, NO-0663 Oslo, Norway; [2]Department of Geriatrics, University Hospital, Oslo, Norway [3]Dept. of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, P.O.Box 5003, NO-1432 Ås, Norway

Introduction

Materials and Methods

Results and Discussion

Conclusions

References

Predicted value vs. AD grading



- Gene expression signature show the same high accuracy independent of AD stage
- The test is useful in detecting very mild to moderate AD.
- Potentially even earlier stages of the disease.

DiaGenic's Product Development Focus

Alzheimers Disease

Parkinsons Disease

Breast Cancer

Parkinson's disease

Project initiated

- Development of DiaGenic's third product candidate, for the early diagnosis of Parkinson's disease has commenced with funding from the Michael J. Fox Foundation
- Based on information on informative probes from its partner in the USA (Dr Clemens Scherzer from Brigham and Women's Hospital) and from our own research, DiaGenic has assembled a gene selection.
- This selection is first being qualified on a RT-PCR based platform before being tested with Parkinson's samples collected from Harvard.

DiaGenic's Product Development Focus

India clinical study

Congress presentations and posters



Interim study reported:

ROC curve from 113 patients



- Grey area = EU/US studies
- AUC India = 0.82
- Ethnic variability has no impact on diagnostic results
- Similar performance for pre- and post-menopausal
  - Improved sensitivity vs published data for mammography in pre-menopausal women
- Final enrolment Feb 08
- Planned launch of India kit mid 08

LABINDIA®

Targeting launch in India in 2008

- Laboratory partner:
  - The Applied Biosystems partner and local distributor in India
  - Our current laboratory for the clinical study
    - Have during the last year demonstrated highly professional laboratory operations using our product and procedures
  - Will, through Applied Biosystem Inc, support new diagnostic assays in the Indian marketplace

- Partner profile:
  - Two shortlisted..

SRL RANBAXY Pathology Laboratories
We care ...

- South East Asia's & India's fastest growing Pathology Services
  - 750 collection centres
  - 321 laboratories
  - 1.100 employees
  - 5 mill patients pr year
- Extensive competencies within molecular diagnostics and experience in launching new diagnostic methods
  - A strategic and broad cooperation

DiaGenic's Indian operations

- Analytical and Molecular diagnostic expertise
- Developer of test and owner of the IP

Diagenic

- Molecular diagnostic expertise
- Blood collection and transport
- Test result report

SRL Ranbaxy

- Analytical molecular expertise
- Blood extraction and PCR analysis

LabIndia

Agenda:

1st Quarter 2008 Presentation

- 1st Quarter Highlights
- 1st Quarter Finance
- Product Development and Clinical Studies
- **Commercial Strategies**
- Outlook

Intellectual Property update

US 20020022222A1

(19) United States

(12) Patent Application Publication

SHARMA et al.

(10) Pub. No.: US 2002/0022222 A1

(43) Pub. Date: Feb. 21, 2002

(54) METHOD OF PREPARING A STANDARD DIAGNOSTIC GENE TRANSCRIPT PATTERN

(76) Inventors: PRAVEEN SHARMA, OSLO (NO); ANDERS LONNEBORG, AAS (NO)

Correspondence Address:
SUGHRUE MION ZINN MACPEAK & SEAS PLLC
2100 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20037-3213

(*) Notice: This is a publication of a continued prosecution application (CPA) filed under 37 CFR 1.53(d).

(21) Appl. No.: 09/429,803

(22) Filed: Oct. 29, 1999

Related U.S. Application Data

(63) Continuation of application No. PCT/GB98/01261, filed on Apr. 30, 1998.

(30) Foreign Application Priority Data

Apr. 30, 1997 (NO) ..... NO 972006

Publication Classification

(51) Int. Cl.[7] C12Q 1/68; C07H 21/02; C07H 21/04; C12P 19/34

(52) U.S. Cl. 435/6; 536/23.1; 435/91.2

(57) ABSTRACT

A method for preparing a gene transcript pattern probe kit characteristic of a disease or condition or a stage thereof in a prokaryotic or eukaryotic organism using mRNA which is differentially expressed in the disease or condition or stage as probes, methods of diagnosis using the method and kits for performing the same are disclosed.

US 20070134656A1

(19) United States

(12) Patent Application Publication

Sharma et al.

(10) Pub. No.: US 2007/0134656 A1

(43) Pub. Date: Jun. 14, 2007

(54) PRODUCT AND METHOD

(76) Inventors: Praveen Sharma, Oslo (NO); Narinder Singh Sahni, Oslo (NO); Anders Lonneborg, Aas (NO)

Correspondence Address:
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON, DC 20037 (US)

(21) Appl. No.: 10/535,414

(22) PCT Filed: Nov. 21, 2003

(86) PCT No.: PCT/GB03/05102

§ 371(c)(1),
(2), (4) Date: May 1, 2006

(30) Foreign Application Priority Data

Nov. 21, 2002 (GB) 0227238.3

Publication Classification

(51) Int. Cl.
C12Q 1/68 (2006.01)
G06F 19/00 (2006.01)
C07H 21/04 (2006.01)

(52) U.S. Cl. 435/6; 702/20; 536/24.3

(57) ABSTRACT

The present invention relates to oligonucleotide probes, for use in assessing gene transcript levels in a cell, which may be used in analytical techniques, particularly diagnosis techniques and kits containing the same.

IP

Status

- Broad IP
  - covers blood based gene signature diagnostics in Alzheimer's disease (US6720138) and (EU03075068.1-2402) and breast cancer
- Three patent family groups
  - Methods for preparing standard diagnostic gene transcript pattern
  - Product and method (includes AD gene set)
  - Oligonulceotides for cancer diagnosis (includes BC gene families)

Patent Status

	Family 1 (WO 98/49342)			Family 2 (WO 2004/046382)			Family 3 (WO 2005/118851)		
Expiry year	2017			2023			2024		
Countries/ Region	G	A	P	G	A	P	G	A	P
US	Alz		BC, MS			G			C
Europe*	G, nSB	Alz							
Europe**						G			C
Norway	G, nSB		G, dD			G			C
Japan			G, dD			G			C
Canada						G			C
Hong Kong	G, nSB					G			C
China						G			C
Australia					Alz, BC				C
New Zealand						G			C
India					Alz, BC				C
South Africa				G					C
ARIPO*						G			C

Abbreviations
Alz: Alzheimer's Disease
BC: Breast cancer
C: Cancer
G: No disease limitation.
G, dD: No disease limitation. Samples collected distant to the area of the disease
G, nSB: No disease limitation. Limited to **onl**y non-sequence based methods.
MS: Multiple sclerosis.

G = Granted
A = Accepted by examiner
P = In-process

1 Research Use Only

H2 07

RUO

-

Research

Use Only

- Documentation needed for:
  - Marketing acceptance
  - New market approaches
- Biomarker for the pharma industry in new drug development and life cycle management
  - Early disease diagnostics
  - Accurate and precise recruitment strategies
    - Include the right patients!
  - Identify responders to treatment
  - Monitor the effect of treatment
  - Identify new indications

Regulatory Compliance

- ISO 13485:2003 Certification
  - Certification of DiaGenic quality management system, Q3/Q4 2008
- CE-mark of Alzheimer's Disease and Breast Cancer assays for the EU market
  - end Q4 2008
- Successful first meeting with the United States Food and Drug Administration (FDA).
  - The purpose of the meeting was mainly to get feedback on DiaGenic's proposal for clinical application of the Alzheimer's test in the USA.

Market Entry Strategy with Revenue Streames

1. Research Use Only (Pharma)
2. Asia Pacific Countries — H2 '08 — 1st Revenues
3. CE (Europe) BC + Alzheimer's — H1 '09
4. Centralized Lab Testing, US
5. Ex EU/US Countries
6. FDA – USA (Alzheimer's)
7. *Screening Approval US*
8. *Screening Approval EU*

Agenda:

1st Quarter 2008 Presentation

- 1st Quarter Highlights
- 1st Quarter Finance
- Product Development and Clinical Studies
- Commercial Strategies
- **Outlook**

Outlook

- DiaGenic will complete the study in India and prepare for the forthcoming product launch together with the selected partners during 2008.
- Communication with selected IVD, pharmaceutical and laboratory companies will continue, supported by new documentation from product development.
- Based on discussions with the FDA, intense work is in progress to prepare for clinical studies on Alzheimer's disease in the USA.
- The objective of a CE mark for marketing and diagnostic use of both DiaGenic's breast cancer and Alzheimer's tests by the end of 2008 is unchanged.

DIAGENIC

DiaGenic ASA
Grenseveien 92, N-0663 Oslo, Norway
Tel +47 23 24 89 50
Mail: diagenic@diagenic.com
www.diagenic.com

20 Largest Share Holders

April 29th 17:00

Shares	Percent	Name
3 543 135	8.10	VERDIPAPIRFONDET NOR V/NORDEA FONDENE AS
2 910 000	6.65	SHARMA PRAVEEN
2 890 000	6.61	LØNNEBORG ERIK ANDERS
1 944 000	4.44	TREDJE AP-FONDEN
1 914 000	4.38	A/S SKARV
1 397 100	3.19	NORDEA BANK SWEDEN A
1 280 900	2.93	JPMBLSA NORDEA LUX LENDING A
1 088 570	2.49	HOLBERG NORDEN V/HOLBERG FONDSFORVA
1 003 100	2.29	LIVSFORSIKRINGSSELSK STRATEGISK
901 000	2.06	SKAGEN VEKST
828 933	1.90	INVESTOR CORPORATE A
785 387	1.80	HOLBERG NORGE V/HOLBERG FONDSFORVA
769 300	1.76	VERDIPAPIRFONDET NOR V/NORDEA FONDENE AS
702 000	1.61	AMFIBIEN AS
646 000	1.48	ANDERSEN RUBEN
476 100	1.09	SANDEN A/S C/O JAN PETTER COLLI
420 000	0.96	HAAVIND KARL WILHELM
410 000	0.94	SEB ENSKILDA ASA EGENHANDELSKONTO
406 378	0.93	STORHAUG DAG
400 000	0.91	STENE IVAR
24 715 903	**56.52**	**Sum**

Breast cancer

- Breast cancer is the most common for of cancers among women with more 600,000 new cases and 150,000 deaths in Europe and the US alone. Early diagnosis and treatments holds the key to survival. This has lead most western countries to establish a screening program for BC. However, the current testing methods - mammography, ultrasound and MRI - all have increasingly recognized limitations. The too low accuracy of mammography especially in women below the age of 50 and in women with dense breasts results in too many missed cancers. There is a clear need for additional and better diagnostic tools, both to improve the detection rate when using conventional mammography, and to select the appropriate patients for the new and costly MRI method. DiaGenic's concept is ideal – peripheral blood is a convenient and easily accessible clinical sample

Parkinson's disease

- Parkinson's disease (PD) is a chronic, degenerative neurological disorder and belongs to a group of conditions called motor system disorders. There is no objective test, or biomarker, for Parkinson's, so the rate of misdiagnosis can be relatively high, especially when the diagnosis is made by a non-specialist. Estimates regarding the number of people in the United States with Parkinson's range from 500,000 to 1,500,000 with 50,000 new cases reported annually. Since Parkinson's is more common in people 60 years old and older, it is expected that the incidence of Parkinson's will increase with the ageing of the baby boomers. Although PD is more common in older persons, some people begin to show symptoms before reach the age of 40. The diagnostic accuracy is only 47% in a community setting, 74% in standard geriatric and neurological practice. Experts in neurological movements disorders achieve 92-98% accuracy.
- The MJ Fox Foundation is funding a DiaGenic study together with Dr Clemens R Scherzer, Assistant Professor of Neurology at Brigham and Womens Hospital and Harvard Medical School to develop the first blood test for Parkinson's disease. This involves identification of, and independent validation of a unique gene expression signature for Parkinson using peripheral blood. Since blood samples have already been collected, the immediate start of the analytical and bioinformatics studies will ensure a rapid development of a prototype of the blood test preceding an approved diagnostic test

Alzheimer's disease

- Alzheimer's disease is the leading cause of dementia and a recent update estimates that more than 20 million people currently have the disease. Even more threatening is that these figures expect to triple in the next 30-40 years. Diagnosis of AD involves a large battery of assessments, including clinical interviews, cognitive function, and, sometimes, also functional imaging and measurements of neurophysiological function. However, with all these tests it is still difficult to make an accurate diagnosis, especially at an early stage of the disease. There are today more that 14 disease modifying drugs in clinical phase III and it is expected that several of them will be on the market in 2 - 4 years time. Efficacy of the new drugs will depend on early diagnosis and thus boost the diagnostic market.